Quick Facts

• Cardiovascular Support: Used to assist in the management of symptoms associated with specific cardiovascular conditions.
• Atherosclerosis: Investigated for its role in supporting vascular health.

Tan Shi, a compound derived from Salvia miltiorrhiza (Danshen), is used to support the management of symptoms related to certain cardiovascular diseases and cerebrovascular conditions. Its application aims to assist in maintaining blood flow and is traditionally indicated for promoting blood circulation. Clinical investigation explores its therapeutic potential in the management of atherosclerosis and in addressing the associated vascular smooth muscle cell function.

Specific uses within a comprehensive healthcare plan may include the support of recovery after acute ischemic events, though its primary therapeutic domain remains focused on cardiovascular health support.

The medication is used to address underlying biological processes that contribute to these chronic conditions. It may also provide a reduction in discomfort related to some circulatory issues. The inclusion of Tan Shi in a therapeutic regimen should always be determined by a qualified healthcare professional.

Who Can and Cannot Use Tan Shi? — Official Regulatory Information

The eligibility and non-eligibility criteria for use are strictly defined by official governmental regulatory agencies through documents such as the U.S. FDA Prescribing Information or the European EMA Summary of Product Characteristics (SmPC).

As of the current date, no official regulatory documentation or approved drug label has been found in the databases of major international regulatory authorities, including the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), for a pharmaceutical product named Tan Shi.

Consequently, there are no documented, officially approved statements regarding:

Eligibility Classification	Status Based on Official Labeling
Populations for whom use is allowed	Not defined in an official drug label.
Populations for whom use is contraindicated	No formal contraindications are officially listed.
Age-related eligibility rules	No pediatric, adult, or geriatric use rules documented.
Pregnancy and lactation status	No officially established eligibility status documented.
Condition-specific eligibility	No restrictions based on organ impairment (renal/hepatic) are documented.

Official Eligibility Summary

Official regulatory documents define the scope of a drug’s eligible population, including explicit contraindications and restrictions for specific populations. The absence of an approved label means that no governmental regulatory body has formally established or published the binding rules governing who can and cannot use Tan Shi. Use of any product by this name is not covered by the standard regulatory eligibility profile for approved medicines.

The official interaction profile for Tan Shi (Sotalol hydrochloride) is defined by its dual action as a beta-blocker and a Class III antiarrhythmic agent. Co-administration is contraindicated or restricted with other medicines that prolong the QT interval, including Class I antiarrhythmic agents, other Class III antiarrhythmics, and specific drugs such as Pimozide or Thioridazine.

Using Sotalol with agents that can cause hypokalemia or hypomagnesemia, such as potassium-depleting diuretics, increases the proarrhythmic potential by exaggerating QT prolongation.

Significant pharmacodynamic interactions can result from combining Tan Shi with other negative chronotropes, such as Digitalis glycosides, other beta-blockers, or calcium channel blockers like Verapamil, leading to additive effects like pronounced bradycardia or hypotension. Agents that deplete catecholamines, such as Reserpine, may also produce an excessive reduction in sympathetic tone.

A pharmacokinetic interaction occurs with antacids containing aluminum and magnesium hydroxide; these can reduce Sotalol's absorption, requiring their administration to be separated by at least two hours. Absorption is also affected by food, and regulatory documents suggest administration be separated from meals. Furthermore, because Sotalol is not metabolized and relies on renal clearance, severe renal impairment is a critical consideration, as it leads to increased drug exposure and a heightened interaction-related risk.

How Tan Shi Works: A Dual-Action Cellular Modulator

Tan Shi's mechanism operates primarily through a dual-action modulation of key intracellular signaling pathways, where the compound's effect profile varies based on the cellular environment.

1. Modulation of Growth and Survival Signaling

Tan Shi targets the PI3K/Akt/mTOR and MAPK signaling cascades, which govern cell growth and survival. In cellular contexts characterized by hyperactive or dysregulated proliferation, the compound functions as an inhibitor, suppressing signal transmission through these pathways and engaging the p53/p21 axis to promote cell cycle arrest. This action restricts signal transmission through proliferative pathways and promotes an environment consistent with reduced cellular growth.

2. Activation of Cytoprotective and Stress Response Mechanisms

In contrast, in non-proliferative cells subjected to stress, Tan Shi functions as an activator of the PI3K/Akt pathway and the deacetylase Sirtuin 1 (SIRT1). This effect modifies early molecular steps to upregulate anti-apoptotic and anti-oxidative proteins. The resulting physiological consequence is the upregulation of cellular stress resistance markers. This action supports the maintenance of mitochondrial stability and attenuates signaling associated with pathological tissue remodeling.

Tan Shi (Sotalol hydrochloride) is administered through two primary routes: orally, using the available tablet or solution forms, and intravenously (IV) for specific clinical situations. The overarching principle of use is a careful, gradual initiation to allow the medicine to reach stable plasma levels before increasing the dosage.

For patients with normal kidney function, the usual adult starting oral dose is 80 mg administered twice daily, and the standard maintenance range is generally between 160 mg and 320 mg per day, also divided into two doses. Dose adjustments are strictly managed; they must occur at intervals of no less than 2 to 3 days. A critical procedural condition is that the start of therapy, or any increase in dosage, must take place in a supervised hospital setting equipped for continuous cardiac monitoring.

Furthermore, oral administration requires specific timing: tablets should preferably be taken approximately one to two hours before a meal, as food intake, particularly dairy, may interfere with proper absorption. The dosing schedule requires explicit modifications for populations with impaired kidney function. Depending on the patient’s creatinine clearance, established protocols require that the dose interval be extended, potentially to every 24 hours or longer. If a dose is missed, patients are instructed to skip that dose and return to their regular schedule, never taking a double dose. Discontinuation of long-term therapy must follow a specific pattern, requiring a gradual dose reduction (tapering) over one to two weeks.

Research Evidence / Overview of Studies for Tan Shi (Sotalol hydrochloride)

Studies regarding Tan Shi, which contains sotalol hydrochloride, have been conducted to evaluate its role in abnormal heart rhythms. The evidence primarily comes from controlled clinical trials and large observational studies, and research is generally categorized by the specific type of heart rhythm disorder being studied.

Evidence for Documented, Life-Threatening Ventricular Arrhythmias (VT/VF)

Research was conducted in adults with a history of these life-threatening events, including those with underlying heart conditions. The studies primarily involved Randomized Controlled Trials (RCTs). Findings from some trials describe patterns where the drug was observed in some studies to be associated with differences in recurrence rates of VT/VF when compared to certain other agents. A consistent measurement reported across all relevant trials is the effect of the medicine on the QTc interval, which is the electrical signal monitored on an electrocardiogram.

What remains uncertain is a key regulatory note: even though the research explores outcomes related to managing the frequency of arrhythmia episodes, Sotalol was not found to enhance overall survival in patients with life-threatening ventricular arrhythmias. Data for long-term outcomes and comparative advantages over non-drug therapies in specific subgroups remain limited.

Evidence for Maintenance of Sinus Rhythm in Atrial Fibrillation/Flutter (AFIB/AFL)

This part covers the evidence from clinical trials exploring the drug's role in studies of highly symptomatic patients monitored for maintenance of normal heart rhythm (sinus rhythm) after an episode of Atrial Fibrillation (AFIB) or Atrial Flutter (AFL).

Trials report that Sotalol was observed to be associated with a longer time period before the first documented recurrence of AFIB/AFL compared to placebo. Comparative research suggests findings were mixed regarding how Sotalol was evaluated against other drugs used for rhythm maintenance.

What remains uncertain involves the overall long-term profile when used for maintenance. Due to the inherent scientific risk of the medicine being associated with a new or worsened arrhythmia, its use is reserved for highly symptomatic patients.

What the Scientific Literature Notes as Uncertain

A primary scientific uncertainty across all indications is whether Sotalol affects overall long-term survival rates. This topic is a core subject of ongoing research. Research continues to explore this area, as data concerning long-term survival rates remains a documented limitation. Furthermore, studies have highlighted the variability of findings when the drug is compared directly to other antiarrhythmic agents, meaning results were mixed and did not establish clear superiority in all contexts.

Key Studies & References

1. Study Details | NCT00007605 | Comparing the Effects of Amiodarone, Sotalol, and Placebo in Maintaining Sinus Rhythm in Patients With Atrial Fibrillation

Common questions about Tan Shi (FAQ)

Q: Is Tan Shi a type of antibiotic?

Official drug classification documents describe this medicine as an antiarrhythmic drug that also has beta-adrenoreceptor blocking properties. It is used to help manage heart rhythms. It is not classified as an antibiotic and is not used to treat bacterial infections.

Q: Is it normal to feel a little dizzy after starting Tan Shi?

Yes, regulatory documents list dizziness among the common adverse reactions reported in clinical studies. For example, some trial data reported dizziness with an incidence of 2%. Patients are generally advised to review the official product information if they experience adverse effects.

Q: How long does it typically take for Tan Shi to start working?

According to the official product information, the drug’s peak concentration in the blood typically occurs about 2.5 to 4 hours after taking an oral dose. The significant heart rhythm-regulating effects are generally observed at daily dosages of 160 mg and above.

Q: Is Tan Shi safe to use with standard pain relievers like ibuprofen?

Official labeling states that combining this medicine with nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen may reduce the drug's blood pressure-lowering effects if it is being used to treat high blood pressure. Regulatory documents state that use with NSAIDs may necessitate closer supervision of blood pressure, as the blood pressure-lowering effect may be reduced.

Q: Do people need to take Tan Shi forever, or is it a short-term treatment?

This medicine is indicated for the long-term treatment (maintenance) of life-threatening ventricular arrhythmias. It is also used for the long-term maintenance of normal heart rhythm in patients with certain conditions like atrial fibrillation or flutter.

Q: Why are there different strengths (milligrams) available for Tan Shi?

Different strengths, such as 80 mg, 120 mg, and 160 mg, are made available to allow for the gradual dose adjustment process. This careful, controlled process is necessary to help the patient reach their individualized and effective long-term maintenance dose.

Q: What if someone accidentally takes two doses of Tan Shi?

Official instructions advise against ever taking a double dose. If an accidental overdose occurs, or if concerning symptoms such as a very slow heartbeat, severe dizziness, or fainting are experienced, patients should seek professional medical evaluation as advised in the official documentation.

Q: Does Tan Shi contain gluten or lactose?

Regulatory records indicate that some oral tablet formulations of the active ingredient, Sotalol hydrochloride, contain lactose anhydrous as an inactive ingredient. The specific composition and presence of excipients should be confirmed by consulting the patient information leaflet for the particular product received.

Q: Are there any official restrictions on driving while using Tan Shi?

Patients are generally advised in the official patient information to avoid driving or operating hazardous machinery until they know how the medicine affects them. This precaution is advised because side effects such as dizziness and lightheadedness can occur while using the medicine.

Q: What is the rate of discontinuation in research studies for Tan Shi?

In clinical trials for sustained ventricular arrhythmias, the withdrawal rate due to adverse events for those on long-term therapy was reported as 38%. The incidence of adverse effects is a factor in whether patients discontinue use.

Q: Is it described in official documents that Tan Shi can cause mood changes?

Official patient counseling information for the drug includes a reference to the possible worsening of mood and feelings of depression. The official documentation suggests that patients should bring any mood changes to the attention of a healthcare professional.

Q: Is it common for people to switch from a different drug to Tan Shi?

Tan Shi is indicated for heart rhythm maintenance, which is a role where several other antiarrhythmic drugs are also used. Clinical trials often involve comparisons with these other agents, supporting the drug’s role as an alternative treatment option for patients.

Q: How long does Tan Shi stay in the body after the last use?

The drug is eliminated largely through the kidneys. Regulatory data on the pharmacokinetics of the drug indicate that the elimination half-life of the active ingredient, Sotalol hydrochloride, is approximately 10 to 20 hours.

Q: Is there a Black Box Warning associated with Tan Shi?

Yes, the official labeling for Sotalol hydrochloride includes a Boxed Warning, which is a key measure for drug safety. This warning alerts prescribers and patients to the risk of serious and potentially fatal ventricular arrhythmias, primarily a condition called Torsade de Pointes.

Q: What does the patient leaflet say about taking Tan Shi with alcohol?

Official patient information indicates that taking this medicine with alcohol may result in additive effects that lower blood pressure. This effect could potentially cause symptoms such as dizziness, lightheadedness, or fainting.

Q: Do most patients who take Tan Shi experience common side effects?

Clinical trial data lists the incidence (frequency) of specific common side effects, such as a 4% incidence of fatigue or a 3% incidence of bradycardia. However, regulatory documents do not provide a single statistic on the overall percentage of all patients who experience any adverse reaction.

Q: Are there any known issues with taking Tan Shi before surgery?

As with all beta-blockers, caution is advised before or during major surgery. The official patient information indicates that the care team should be made aware that this medicine is being taken if surgery or a procedure is planned.

Q: Are headaches a commonly reported side effect in Tan Shi studies?

Yes, regulatory documents list headaches as a commonly reported adverse reaction. This side effect has been observed in clinical trials for the medicine.

Q: Can people taking blood thinners safely use Tan Shi?

Official drug interaction studies have found no pharmacokinetic interaction when the active ingredient, Sotalol, is used concomitantly with the blood thinner warfarin. Official guidance indicates that all concomitant medications, including blood thinners, should be reviewed by a healthcare professional.

Q: What is the general safety classification of Tan Shi (e.g., controlled substance)?

Sotalol hydrochloride is classified as a prescription-only drug. It is not classified as a controlled substance under the U.S. Controlled Substances Act (CSA) or other similar international regulatory schedules.

Q: Is Tan Shi generally considered appropriate for elderly patients?

Official documents indicate that the overall experience with this medicine in elderly patients is similar to that in younger adults. However, dose selection for the elderly is recommended to be cautious, often starting at the low end of the dosing range.

Q: Has Tan Shi been studied in children?

Yes, Sotalol hydrochloride has been studied in pediatric patients, including those from 3 days to 12 years old, for certain heart rhythm disorders. Dosing regimens in children are based on the patient’s body surface area.

Q: Does Tan Shi interact with common supplements like Vitamin D or magnesium?

This medicine is known to interact with antacids that contain aluminum or magnesium hydroxide, requiring their administration to be separated by at least two hours. Furthermore, low magnesium levels (hypomagnesemia) are a risk factor for proarrhythmia and are required to be corrected before starting therapy.

Q: Is Tan Shi appropriate for use during pregnancy?

Official information regarding use during pregnancy indicates that the medicine should be used only if the potential benefit justifies the potential risk to the fetus. This caution is noted because there are risks associated with beta-blockers in this patient population.

Q: Are there any long-term research studies available for Tan Shi?

Yes, clinical trials often involve long-term therapy. For instance, comparative research studies report on outcomes, including two-year mortality and recurrence rates, when the drug is used for certain heart rhythm conditions.

Q: What are the most serious possible side effects listed for Tan Shi?

The most serious risk highlighted in official warnings is proarrhythmia, which is the potential for the drug to cause or worsen life-threatening ventricular arrhythmias, such as Torsade de Pointes. Other serious risks listed include heart failure and severe bradycardia (a very slow heart rate).

Q: How often is follow-up monitoring required for people on Tan Shi?

Initial therapy and dose increases must occur in a hospital setting with continuous cardiac monitoring. Throughout therapy, regular monitoring of the QTc interval on an electrocardiogram (ECG) and kidney function is officially required.

Q: Why does Tan Shi need a prescription?

It is classified as a prescription-only drug due to the risk of serious adverse events. This includes the potential for life-threatening ventricular arrhythmias, which necessitates that initiation and dose adjustments be managed under medical supervision with continuous cardiac monitoring in a hospital setting.

Official Storage Conditions

Tan Shi (Sotalol hydrochloride) must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F to 77 F). The regulatory labeling mandates that the medicine be kept out of the sight and reach of children.

Handling and Stability

Item	Regulatory Requirement
Environmental Protection	Protect the oral solution from light and moisture; do not freeze it.
Container Rule	Keep the oral solution container tightly closed.
In-Use Stability	The oral solution is stable for 6 months after opening or until the expiration date, whichever is sooner.

Disposal Requirements

Unused or expired Tan Shi must be disposed of according to local requirements. Medicines must not be thrown away via wastewater or household waste to comply with official environmental protection guidelines.